Needham & Company
View Older Stories
-
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
M&A watch: 3 biotech companies that are most likely to be acquired - Needham
-
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Vaxcyte, Inc (PCVX) Prices 10.94M Share and Warrant Offering at $64/sh
-
Vaxcyte Announces Pricing of $750 Million Public Offering
-
Vaxcyte, Inc (PCVX) Announces Proposed Share and Warrant Offering
-
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Vaxcyte, Inc (PCVX) Prices 11.2M Share and Warrant Offering at $41/sh
-
Vaxcyte Announces Pricing of $500 Million Public Offering
-
Vaxcyte Announces Pricing of $500 Million Public Offering
-
Vaxcyte, Inc (PCVX) Commences Proposed Stock Offering, Size not Disclosed
-
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Vaxcyte, Inc (PCVX) Prices $600M Offering at $32/sh
-
Vaxcyte Announces Pricing of $600 Million Public Offering
-
Vaxcyte Announces Pricing of $600 Million Public Offering
-
Vaxcyte (PCVX) Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Vaxcyte's (PCVX) Approach Has Potential to Disrupt PCV Market - Needham & Company Reiterates Buy Rating with $52 Price Target
-
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
-
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
-
Needham & Company Reiterates Buy Rating on Vaxcyte (PCVX)
-
Vaxcyte, Inc (PCVX) Prices 2.5M Share IPO at $20/sh
-
Vaxcyte Announces Pricing of $100 Million Public Offering
-
Vaxcyte Announces Pricing of $100 Million Public Offering
-
Vaxcyte, Inc (PCVX) Announces Proposed Stock and Warrant Offering
-
Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference
-
Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference
-
UPDATE: Needham & Company Starts Vaxcyte (PCVX) at Buy
-
Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Vaxcyte, Inc. (PCVX) IPO opens at $20.80 after pricing at $16

